4.8 Review

Immune Signaling by RIG-I-like Receptors

Journal

IMMUNITY
Volume 34, Issue 5, Pages 680-692

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2011.05.003

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [R01 AI060389-09, R01 AI060389-08, U19 AI088778-02, U19 AI088778-01, U19 AI083019, R01 AI060389, R21 AI057568-02, U19 AI088778-03, U19 AI083019-02S1, R21 AI057568-03, R21 AI057568-01A2, U19 AI083019-02, U19 AI083019-03, R01 AI060389-10, U19 AI088778, R01 AI060389-07, U19 AI083019-01, R01 AI060389-11, U19 AI083019-04, R21 AI057568] Funding Source: Medline
  2. NIDA NIH HHS [R01 DA024563-04, R01 DA024563-01, R01 DA024563, R01 DA024563-03, R01 DA024563-05, R01 DA024563-02] Funding Source: Medline

Ask authors/readers for more resources

The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity. The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection. Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response. RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications. Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases. Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available